Abiraterone Acetate; Niraparib Tosylate Patent Expiration

Abiraterone Acetate; Niraparib Tosylate is used for treating metastatic castration-resistant prostate cancer associated with a deleterious BRCA mutation. It was first introduced by Janssen Biotech Inc in its drug Akeega on Aug 11, 2023.


Abiraterone Acetate; Niraparib Tosylate Patents

Given below is the list of patents protecting Abiraterone Acetate; Niraparib Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Akeega US11091459 Niraparib compositions Mar 27, 2038 Janssen Biotech
Akeega US11207311 Method of treating prostate cancer Jul 28, 2037 Janssen Biotech
Akeega US11673877 Niraparib compositions Mar 27, 2038 Janssen Biotech
Akeega US8071579 DNA damage repair inhibitors for the treatment of cancer Aug 12, 2027 Janssen Biotech
Akeega US8071623 Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors Mar 27, 2031 Janssen Biotech
Akeega US8143241 DNA damage repair inhibitors for treatment of cancer Aug 12, 2027 Janssen Biotech
Akeega US8436185 Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide Apr 24, 2029 Janssen Biotech
Akeega US8859562 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug 04, 2031 Janssen Biotech


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳